Monitor the November 6-7 data presentations for safety and efficacy results of the brenetafusp combination. Positive data could support expansion of the PRAME-targeting pipeline and combination strategy, while negative data would be a setback. No financial impact until data is released.
Price Chart
Executive Summary
Immunocore announced it will present Phase 1/2 data for brenetafusp (PRAME-targeting ImmTAC) alone and in combination with KIMMTRAK in metastatic uveal melanoma at the 2026 SITC meeting, including a late-breaking oral session. The data release is scheduled for November 6-7, 2026. No clinical results are disclosed in this press release, so the event is a data presentation announcement with no material financial impact yet.
Key Facts
- Immunocore will present Phase 1/2 data for brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive metastatic uveal melanoma at SITC 2026
- Data will be presented in a poster session on November 6 and an oral late-breaking session on November 7, 2026
- Brenetafusp is Immunocore's first PRAME-targeting bispecific ImmTAC molecule
- KIMMTRAK (tebentafusp-tebn) is already approved in 39 countries for metastatic uveal melanoma
- No clinical efficacy or safety data were disclosed in this press release
Financial Impact
No financial data disclosed; the presentation is a data readout announcement with no results yet
Risk Factors
- No clinical data disclosed; the presentation is an announcement only
- Combination of two T cell engagers carries unknown safety and efficacy risks
- Forward-looking statements subject to clinical trial risks and regulatory uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391299 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | Press Release | $31.27 | awaiting T+60 | awaiting T+60 | $30.49 (−2.49%) |
Oct 15, 2026 17d ago | Press Release | $29.48 | awaiting T+60 | awaiting T+60 | $30.49 (+3.43%) |
Oct 7, 2026 25d ago | SC 13G/A | $29.41 | awaiting T+60 | awaiting T+60 | $30.49 (+3.67%) |
Sep 14, 2026 6w ago | 8-K | $32.46 | awaiting T+60 | awaiting T+60 | $30.49 (−6.07%) |
Aug 6, 2026 12w ago | 8-K | $34.50 $30.49 | ▼ −11.62% | ▼ −9.95% | $30.49 (−11.62%) |
May 31, 2026 22w ago | Press Release | $29.13 $37.40 | ▲ +28.39% | ▲ +27.16% | $30.49 (+4.67%) |
Apr 19, 2026 28w ago | Press Release | $31.46 $34.68 | ▲ +10.24% | ▲ +3.46% | $30.49 (−3.08%) |
Apr 8, 2026 29w ago | 144 | $31.85 $32.50 | ▲ +2.04% | ▼ −8.42% | $30.49 (−4.27%) |
Mar 17, 2026 32w ago | Press Release | $30.04 $28.62 | ▼ −4.73% | ▼ −16.25% | $30.49 (+1.50%) |
Feb 25, 2026 35w ago | 8-K | $32.16 $29.54 | ▼ −8.15% | ▼ −15.10% | $30.49 (−5.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers